Read by QxMD icon Read


Neha Prakash, Chelsea Caspell-Garcia, Christopher Coffey, Andrew Siderowf, Caroline M Tanner, Karl Kieburtz, Brit Mollenhauer, Douglas Galasko, Kalpana Merchant, Tatiana Foroud, Lana M Chahine, Daniel Weintraub, Cindy Casaceli, Ray Dorsey, Renee Wilson, Margaret Herzog, Nichole Daegele, Vanessa Arnedo, Mark Frasier, Todd Sherer, Ken Marek, Tanya Simuni
OBJECTIVE: To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). BACKGROUND: Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. DESIGN/METHODS: Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers...
January 31, 2019: Parkinsonism & related Disorders
Klaus Romero, Daniela Conrado, Jackson Burton, Timothy Nicholas, Vikram Sinha, Sreeraj Macha, Malidi Ahamadi, Jesse Cedarbaum, John Seibyl, Kenneth Marek, Peter Basseches, Derek Hill, Ed Somer, Jill Gallagher, David T Dexter, Arthur Roach, Diane Stephenson
The Critical Path for Parkinson's (CPP) Imaging Biomarker and Modeling and Simulation working groups aimed to achieve qualification opinion by the European Medicines Agency's (EMA) Committee for Medical Products for Human Use (CHMP) for the use of baseline dopamine transporter (DAT) neuroimaging for patient selection in early Parkinson disease (PD) clinical trials. This manuscript describes the regulatory science strategy to achieve this goal. CPP is an international consortium of 3 Parkinson's charities and 9 pharmaceutical partners, coordinated by Critical Path Institute)...
February 1, 2019: Clinical and Translational Science
L M Chahine, A Iranzo, A Fernández-Arcos, T Simuni, N Seedorff, C Caspell-Garcia, A W Amara, C Comella, B Högl, J Hamilton, K Marek, G Mayer, B Mollenhauer, R Postuma, E Tolosa, C Trenkwalder, A Videnovic, W Oertel
REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson's Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included...
2019: NPJ Parkinson's Disease
Xi Zhang, Jingyuan Chou, Jian Liang, Cao Xiao, Yize Zhao, Harini Sarva, Claire Henchcliffe, Fei Wang
Parkinson's disease (PD) is associated with diverse clinical manifestations including motor and non-motor signs and symptoms, and emerging biomarkers. We aimed to reveal the heterogeneity of PD to define subtypes and their progression rates using an automated deep learning algorithm on the top of longitudinal clinical records. This study utilizes the data collected from the Parkinson's Progression Markers Initiative (PPMI), which is a longitudinal cohort study of patients with newly diagnosed Parkinson's disease...
January 28, 2019: Scientific Reports
Soeren Mattke, Mark Hanson, Anissa C Dallmann, Marc Bentele
OBJECTIVES: The study estimated the health economic impact of a latest generation coronary stent with ultrathin struts and bioresorbable polymer coating. BACKGROUND: The recent BIOFLOW V trial, an international FDA approval trial ( NCT02389946), has shown that an ultrathin, bioresorbable polymer sirolimus-eluting stent had a significantly lower rate of target lesion failure and target vessel-related myocardial infarction than a thin, durable polymer everolimus-eluting stent at 12 months, driven by a lower rate of peri-procedural myocardial infarction (ppMI)...
November 20, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Claudio Liguori, Federico Paolini Paoletti, Fabio Placidi, Roberta Ruffini, Giulia Maria Sancesario, Paolo Eusebi, Nicola Biagio Mercuri, Lucilla Parnetti
PURPOSE OF REVIEW: Idiopathic REM sleep behavior disorder (iRBD) is one of the most significant prodromal manifestations of synucleinopathies. Different predictive biomarkers for iRBD conversion have been investigated, but scarce data are present in literature about the predictive role of cerebrospinal fluid (CSF) biomarkers. In this review, we focus on CSF biomarkers in patients with both iRBD and RBD associated with synucleinopathies to explore their potential predictive power. RECENT FINDINGS: Recent studies revealed that CSF α-synuclein levels are higher in Parkinson's disease (PD) patients with RBD compared to those without RBD, even if α-synuclein does not seem to predict conversion of iRBD into PD...
January 14, 2019: Current Neurology and Neuroscience Reports
Frederic Sampedro, Juan Marín-Lahoz, Saul Martínez-Horta, Javier Pagonabarraga, Jaime Kulisevsky
The COMT Val158 Met polymorphism has recently been identified as a predictor for cognitive decline in Parkinson's disease (PD). However, it remains unknown whether an early brain structural compromise could be involved in this clinical association. Here, in a cohort of 120 cognitively preserved de novo PD patients from the Parkinson's Progression Markers Initiative (PPMI) database, we found a widespread reduction in cerebral gray matter volume (GMV) in patients harboring the Val/Val genotype. The atrophic pattern included fronto-subcortical and parieto-temporal territories...
January 5, 2019: Brain Imaging and Behavior
Lu Chen, Jun Shi, Bo Peng, Yakang Dai
Feature representation is the crucial factor for the magnetic resonance imaging (MRI) based computer-aided diagnosis (CAD) of Parkinson's disease (PD). Deep polynomial network (DPN) is a novel supervised deep learning algorithm, which has excellent feature representation for small dataset. In this work, a stacked DPN (SDPN) based ensemble learning framework is proposed for diagnosis of PD, which can improve diagnostic accuracy for small dataset. In the proposed framework, SDPN was performed on each subset of extracted features from MRI images to generate new feature representation...
June 1, 2018: Sheng Wu Yi Xue Gong Cheng Xue za Zhi, Journal of Biomedical Engineering, Shengwu Yixue Gongchengxue Zazhi
Michael Michail, James N Cameron, Nitesh Nerlekar, Abdul Rahman Ihdayhid, Liam M McCormick, Robert Gooley, Giampaolo Niccoli, Filippo Crea, Rocco A Montone, Adam J Brown
BACKGROUND: The aim was to assess whether periprocedural myocardial injury (PPMI) predicts outcomes in patients undergoing transcatheter aortic valve replacement (TAVR). PPMI is a strong predictor of outcomes following coronary intervention, but its impact in the context of TAVR remains unclear. We performed a systematic review and meta-analysis to ascertain the association between PPMI and short- or long-term outcomes. METHODS AND RESULTS: Electronic searches identified studies reporting PPMI following TAVR...
November 2018: Circulation. Cardiovascular Interventions
Kenneth Marek, Sohini Chowdhury, Andrew Siderowf, Shirley Lasch, Christopher S Coffey, Chelsea Caspell-Garcia, Tanya Simuni, Danna Jennings, Caroline M Tanner, John Q Trojanowski, Leslie M Shaw, John Seibyl, Norbert Schuff, Andrew Singleton, Karl Kieburtz, Arthur W Toga, Brit Mollenhauer, Doug Galasko, Lana M Chahine, Daniel Weintraub, Tatiana Foroud, Duygu Tosun-Turgut, Kathleen Poston, Vanessa Arnedo, Mark Frasier, Todd Sherer
Objective: The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker-defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease (PD) progression markers to accelerate disease-modifying therapeutic trials. Methods: A total of 423 untreated PD, 196 Healthy Control (HC) and 64 SWEDD (scans without evidence of dopaminergic deficit) subjects were enrolled at 24 sites...
December 2018: Annals of Clinical and Translational Neurology
Amy W Amara, Lana Chahine, Nicholas Seedorff, Chelsea J Caspell-Garcia, Christopher Coffey, Tanya Simuni
INTRODUCTION: This study investigates longitudinal changes in self-reported physical activity, measured by Physical Activity Scale of the Elderly (PASE), in early Parkinson's disease (PD) and matched healthy control (HC) participants in the Parkinson's Progression Marker Initiative (PPMI) and evaluates associations between physical activity and PD progression. METHODS: PPMI is a prospective, longitudinal study evaluating markers of progression in PD participants who are unmedicated at enrollment...
December 10, 2018: Parkinsonism & related Disorders
Ryul Kim, Joongyub Lee, Han-Joon Kim, Aryun Kim, Mihee Jang, Beomseok Jeon, Un Jung Kang
OBJECTIVE: To determine whether CSF biomarkers can be used as a predictor of freezing of gait (FOG) in Parkinson disease (PD) and to investigate the predictive value of clinical, dopamine transporter (DAT) imaging, and CSF parameters both separately and in combination. METHODS: This study using the PPMI data included 393 patients with newly diagnosed PD without FOG at baseline. We evaluated CSF for β-amyloid 1-42 (Aβ42 ), α-synuclein, total tau, phosphorylated tau181 , and the calculated ratio of Aβ42 to total tau at baseline...
January 1, 2019: Neurology
Paolo Eusebi, Michele Romoli, Federico Paolini Paoletti, Nicola Tambasco, Paolo Calabresi, Lucilla Parnetti
Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson's disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson's Progression Markers Initiative (PPMI). This retrospective cohort study included all PD patients enrolled in the PPMI cohort. Main outcome was the incidence rate of dyskinesia, defined as the first time the patient reported a non-zero score in the item "Time spent with dyskinesia" of the MDS-UPDRS part IV...
2018: NPJ Parkinson's Disease
Farzaneh Ghazi Sherbaf, Bahram Mohajer, Amir Ashraf-Ganjouei, Mahtab Mojtahed Zadeh, Ali Javinani, Hossein Sanjari Moghaddam, Mehdi Shirin Shandiz, Mohammad Hadi Aarabi
Background: Growing evidence shows that impaired signaling of Insulin-like Growth Factor-1 (IGF-1) is associated with neurodegenerative disorders, such as Parkinson's disease (PD). However, there is still controversy regarding its proinflammatory or neuroprotective function. In an attempt to elucidate the contribution of IGF-1 in PD, we aimed to discover the relation between serum IGF-1 levels in drug-naïve early PD patients and cerebrospinal fluid (CSF) biomarkers as well as microstructural changes in brain white matter...
2018: Frontiers in Endocrinology
B Gonska, M Keßler, J Wöhrle, W Rottbauer, J Seeger
OBJECTIVE: Permanent pacemaker implantation (PPMI) after transcatheter aortic valve implantation (TAVI) is the most common complication after the procedure. PPMI rates remain high with the new-generation TAVI devices despite improved outcomes concerning paravalvular aortic regurgitation and vascular access complications. However, the impact of PPMI on mortality and clinical outcome is still a matter of debate, and data with new-generation devices on this matter are scarce. Therefore, we sought to analyse the influence of PPMI in patients treated with the new-generation devices on one-year outcome...
November 15, 2018: Netherlands Heart Journal
Kirsten I Taylor, Fabio Sambataro, Frank Boess, Alessandro Bertolino, Juergen Dukart
Background: Progressive neuronal loss in neurodegenerative diseases such as Parkinson's disease (PD) is associated with progressive degeneration of associated white matter tracts as measured by diffusion tensor imaging (DTI). These findings may have diagnostic and functional implications but their value in de novo PD remains unknown. Here we analyzed longitudinal DTI data from Parkinson's Progression Markers Initiative de novo PD patients for changes over time relative to healthy control (HC) participants. Methods: Baseline and 1-year follow-up DTI MRI data from 71 PD patients and 45 HC PPMI participants were included in the analyses...
2018: Frontiers in Aging Neuroscience
Maowen Ba, Guoping Yu, Min Kong, Hui Liang, Ling Yu
Background: Rapid eye movement sleep behavior disorder (RBD) is associated with cognitive decline in early Parkinson's disease (PD). However, the underlyling basis for this association remains unclear. Methods: Parkinson's Progression Marker's Initiative (PPMI) subjects underwent baseline RBD testing with RBD sleep questionnaire (RBDSQ). Serial assessments included measures of motor symptoms, non-motor symptoms (NMS), neuropsychological assessment, blood and cerebrospinal fluid (CSF) biomarkers...
2018: Translational Neurodegeneration
Frederic Sampedro, Juan Marín-Lahoz, Saul Martínez-Horta, Javier Pagonabarraga, Jaime Kulisevsky
The role of cerebrospinal fluid (CSF) biomarkers such as CSF α-synuclein and CSF tau in predicting cognitive decline in Parkinson's disease (PD) continues to be inconsistent. Here, using a cohort of de novo PD patients with preserved cognition from the Parkinson's Progression Markers Initiative (PPMI), we show that the SNCA rs356181 single nucleotide polymorphism (SNP) modulates the effect of these CSF biomarkers on cortical thinning. Depending on this SNP's genotype, cortical atrophy was associated with either higher or lower CSF biomarker levels...
October 18, 2018: Neuro-degenerative Diseases
Andrew J Petkus, J Vincent Filoteo, Dawn M Schiehser, Megan E Gomez, Giselle Petzinger
OBJECTIVE: Symptoms of anxiety, depression commonly co-occur with cognitive decline in patients with Parkinson's disease (PD). The directionality of this association is unclear, however, in that poor cognitive performance may lead to increased symptoms of anxiety and depression or higher anxiety and depressive symptoms may lead to cognitive decline. The purpose of this study was to elucidate the directionality of the association between symptoms of anxiety and depression with cognitive performance in newly diagnosed patients with PD...
October 18, 2018: Neuropsychology
Andrés Ortiz, Jorge Munilla, Francisco J Martínez-Murcia, Juan M Górriz, Javier Ramírez
Medical image classification is currently a challenging task that can be used to aid the diagnosis of different brain diseases. Thus, exploratory and discriminative analysis techniques aiming to obtain representative features from the images play a decisive role in the design of effective Computer Aided Diagnosis (CAD) systems, which is especially important in the early diagnosis of dementia. In this work, we present a technique that allows using specific time series analysis techniques with 3D images. This is achieved by sampling the image using a fractal-based method which preserves the spatial relationship among voxels...
August 29, 2018: International Journal of Neural Systems
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"